A 5-Question Quiz on Breast Cancer

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.